Skip to main content

Genprex Inc

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

GNPX$2.06-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Statements of Cash Flows

Year Ended
December 31,
20242023
Cash flows from operating activities:
Net loss$(21,111,163)$(30,860,461)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation6,69315,004
Share-based compensation and issuance of stock for services3,302,9825,408,728
Intellectual property773,478—
Changes in operating assets and liabilities:
Accounts receivable—34,852
Prepaid expenses and other328,330(298,096)
Research and development supplies300,630517,449
Accounts payable(323,315)954,686
Other current liabilities(426,723)(510,765)
Net cash used in operating activities(17,149,088)(24,738,603)
Cash flows from investing activities:
Disposals of property and equipment1,166169
Additions to intellectual property—(71,383)
Net cash provided by (used in) investing activities1,166(71,214)
Cash flows from financing activities:
Net proceeds from issuances of common stock12,011,95310,593,377
Net cash provided by financing activities12,011,95310,593,377
Net decrease in cash(5,135,969)(14,216,440)
Cash and cash equivalents, beginning of year6,737,62920,954,069
Cash and cash equivalents, end of year$1,601,660$6,737,629
Supplemental schedule of non-cash investing and financing activities:
Deemed dividend related to warrant modification$(277,119)—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.